Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 1/2016

01-02-2016 | Osteocytes (T Bellido and J Klein-Nulend, Section Editors)

The Role of Osteocytes in Age-Related Bone Loss

Authors: Robert L. Jilka, Charles A. O’Brien

Published in: Current Osteoporosis Reports | Issue 1/2016

Login to get access

Abstract

The decrease in bone mass and strength during aging has multiple causes. Osteocytes are long-lived cells within the bone matrix that perform a variety of functions, including the control of bone remodeling. Because of their longevity, osteocytes are more likely than osteoclasts or osteoblasts to accumulate molecular damage over time. Osteocytes utilize quality-control pathways like autophagy to remove damaged organelles and macromolecules, and thereby maintain function. When the damage is excessive, cell death pathways such as apoptosis minimize the impact of potential osteocyte dysfunction on the skeleton. The goal of this review is to discuss how dysregulation of these pathways in osteocytes may contribute to the decline in bone mass and strength with age.
Literature
1.
Parfitt AM. Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. Bone. 2002;30(1):5–7.PubMedCrossRef
2.
Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21(2):115–37.PubMed
3.
Palumbo C, Cavani F, Sena P, Benincasa M, Ferretti M. Osteocyte apoptosis and absence of bone remodeling in human auditory ossicles and scleral ossicles of lower vertebrates: a mere coincidence or linked processes? Calcif Tissue Int. 2012;90(3):211–8.PubMedCrossRef
4.
Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315–23.PubMedCrossRef
5.
Jilka RL, O'Brien CA, Bartell SM, Weinstein RS, Manolagas SC. Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms. J Bone Miner Res. 2010;25(11):2427–37.PubMedPubMedCentralCrossRef
6.
Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12(9):1260–8.PubMedPubMedCentralCrossRef
7.
8.
Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17(10):1231–4.PubMedCrossRef
9.••
Xiong J, Piemontese M, Onal M, Campbell J, Goellner JJ, Dusevich V, et al. Osteocytes, not osteoblasts or lining cells, are the main source of the RANKL required for osteoclast formation in remodeling bone. PLoS One. 2015;10(9):e0138189. Uses a genetic approach to show that osteocytes produce the RANKL needed for osteoclastogenesis in murine trabecular bone.PubMedPubMedCentralCrossRef
10.
Kim S, Yamazaki M, Zella LA, Shevde NK, Pike JW. Activation of receptor activator of NF-{kappa}B ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers. Mol Cell Biol. 2006;26(17):6469–86.PubMedPubMedCentralCrossRef
11.
Galli C, Zella LA, Fretz JA, Fu Q, Pike JW, Weinstein RS, et al. Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass. Endocrinology. 2008;149(1):146–53.PubMedPubMedCentralCrossRef
12.
Fu Q, Manolagas SC, O'Brien CA. Parathyroid hormone controls receptor activator of NF-{kappa}B ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol. 2006;26(17):6453–68.PubMedPubMedCentralCrossRef
13.•
Kennedy OD, Herman BC, Laudier DM, Majeska RJ, Sun HB, Schaffler MB. Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations. Bone. 2012;50(5):1115–22. Showed that dying osteocytes signal neighboring viable osteocytes to increased synthesis of RANKL.PubMedPubMedCentralCrossRef
14.
Wang M, Vanhouten JN, Nasiri AR, Tommasini SM, Broadus AE. Periosteal PTHrP regulates cortical bone modeling during linear growth in mice. J Anat. 2014;225(1):71–82.PubMedPubMedCentralCrossRef
15.
Brunkow ME, Gardner JC, Van NJ, Paeper BW, Kovacevich BR, Proll S, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577–89.PubMedPubMedCentralCrossRef
16.
Balemans W, Patel N, Ebeling M, Van HE, Wuyts W, Lacza C, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39(2):91–7.PubMedPubMedCentralCrossRef
17.
Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280(20):19883–7.PubMedCrossRef
18.
Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res. 2009;24(10):1651–61.PubMedCrossRef
19.
Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012;Jun 20.
20.
Ominsky MS, Niu QT, Li C, Li X, Ke HZ. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J Bone Miner Res. 2014;29(6):1424–30.PubMedCrossRef
21.
Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 2007;5(6):464–75.PubMedCrossRef
22.
Kwon RY, Meays DR, Meilan AS, Jones J, Miramontes R, Kardos N, et al. Skeletal adaptation to intramedullary pressure-induced interstitial fluid flow is enhanced in mice subjected to targeted osteocyte ablation. PLoS One. 2012;7(3):e33336.PubMedPubMedCentralCrossRef
23.
Xiao Z, Dallas M, Qiu N, Nicolella D, Cao L, Johnson M, et al. Conditional deletion of Pkd1 in osteocytes disrupts skeletal mechanosensing in mice. FASEB J. 2011;25(7):2418–32.PubMedPubMedCentralCrossRef
24.
Qiu N, Xiao Z, Cao L, Buechel MM, David V, Roan E, et al. Disruption of Kif3a in osteoblasts results in defective bone formation and osteopenia. J Cell Sci. 2012;125(Pt 8):1945–57.PubMedPubMedCentralCrossRef
25.
You L, Temiyasathit S, Lee P, Kim CH, Tummala P, Yao W, et al. Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading. Bone. 2008;42(1):172–9.PubMedPubMedCentralCrossRef
26.
Robling AG, Niziolek PJ, Baldridge LA, Condon KW, Allen MR, Alam I, et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2008;283(9):5866–75.PubMedCrossRef
27.
Tu X, Rhee Y, Condon KW, Bivi N, Allen MR, Dwyer D, et al. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. Bone. 2012;50(1):209–17.PubMedPubMedCentralCrossRef
28.
Brown EM, Juppner H. Parathyroid hormone: synthesis, secretion, and action. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Sixthth ed. Washington, D.C: American Society for Bone and Mineral Research; 2006. p. 90–9.
29.
Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, et al. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology. 2001;142(9):4047–54.PubMed
30.
Onal M, Galli C, Fu Q, Xiong J, Weinstein RS, Manolagas SC, et al. The RANKL distal control region is required for the increase in RANKL expression, but not the bone loss, associated with hyperparathyroidism or lactation in adult mice. Mol Endocrinol. 2012;26(2):341–8.PubMedPubMedCentralCrossRef
31.•
Saini V, Marengi DA, Barry KJ, Fulzele KS, Heiden E, Liu X, et al. Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH. J Biol Chem. 2013;288(28):20122–34. Shows that direct actions of PTH on osteocytes regulate bone formation and resorption.PubMedPubMedCentralCrossRef
32.
Powell Jr WF, Barry KJ, Tulum I, Kobayashi T, Harris SE, Bringhurst FR, et al. Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeostatic calcemic responses. J Endocrinol. 2011;209(1):21–32.PubMedPubMedCentralCrossRef
33.
34.••
Qing H, Ardeshirpour L, Pajevic PD, Dusevich V, Jahn K, Kato S, et al. Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J Bone Miner Res. 2012;27(5):1018–29. Shows that osteocytes control their lacunar space.PubMedPubMedCentralCrossRef
35.
36.
Farrow EG, Summers LJ, Schiavi SC, McCormick JA, Ellison DH, White KE. Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation. J Endocrinol. 2010;207(1):67–75.PubMedPubMedCentralCrossRef
37.
Segawa H, Kawakami E, Kaneko I, Kuwahata M, Ito M, Kusano K, et al. Effect of hydrolysis-resistant FGF23-R179Q on dietary phosphate regulation of the renal type-II Na/Pi transporter. Pflugers Arch. 2003;446(5):585–92.PubMedCrossRef
38.
Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19(3):429–35.PubMedCrossRef
39.
Bai XY, Miao DS, Li JR, Goltzman D, Karaplis AC. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology. 2004;145(11):5269–79.PubMedCrossRef
40.
41.
Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev. 2010;31:266–300.PubMedPubMedCentralCrossRef
42.
Khosla S. Pathogenesis of age-related bone loss in humans. J Gerontol Ser A Biol Med Sci. 2013;68(10):1226–35.CrossRef
43.
Zebaze RM, Ghasem-Zadeh A, Bohte A, Iuliano-Burns S, Mirams M, Price RI, et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet. 2010;375(9727):1729–36.PubMedCrossRef
44.
Nicks KM, Amin S, Atkinson EJ, Riggs BL, Melton III LJ, Khosla S. Relationship of age to bone microstructure independent of areal bone mineral density. J Bone Miner Res. 2012;27(3):637–44.PubMedPubMedCentralCrossRef
45.••
Bala Y, Zebaze R, Seeman E. Role of cortical bone in bone fragility. Curr Opin Rheumatol. 2015;27(4):406–13. Provides a comprehensive view of the origins and significance of cortical porosity in aging humans.PubMedCrossRef
46.
Han ZH, Palnitkar S, Rao DS, Nelson D, Parfitt AM. Effect of ethnicity and age or menopause on the structure and geometry of iliac bone. J Bone Miner Res. 1996;11(12):1967–75.PubMedCrossRef
47.
Schaffler MB, Burr DB. Stiffness of compact bone: effects of porosity and density. J Biomech. 1988;21(1):13–6.PubMedCrossRef
48.
Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, Roberson PK, et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem. 2007;282(37):27285–97.PubMedPubMedCentralCrossRef
49.
Glatt V, Canalis E, Stadmeyer L, Bouxsein ML. Age-related changes in trabecular architecture differ in female and male C57BL/6J mice. J Bone Miner Res. 2007;22(8):1197–207.PubMedCrossRef
50.
Vanhooren V, Libert C. The mouse as a model organism in aging research: usefulness, pitfalls and possibilities. Ageing Res Rev. 2013;12(1):8–21.PubMedCrossRef
51.
Weiss A, Arbell I, Steinhagen-Thiessen E, Silbermann M. Structural changes in aging bone: osteopenia in the proximal femurs of female mice. Bone. 1991;12(3):165–72.PubMedCrossRef
52.
Silbermann M, Weiss A, Reznick AZ, Eilam Y, Szydel N, Gershon D. Age-related trend for osteopenia in femurs of female C57BL/6 mice. Compr Gerontol A. 1987;1:45–51.PubMed
53.
Ferguson VL, Ayers RA, Bateman TA, Simske SJ. Bone development and age-related bone loss in male C57BL/6J mice. Bone. 2003;33(3):387–98.PubMedCrossRef
54.•
Jilka RL, O'Brien CA, Roberson PK, Bonewald LF, Weinstein RS, Manolagas SC. Dysapoptosis of osteoblasts and osteocytes increases cancellous bone formation but exaggerates bone porosity with age. J Bone Miner Res. 2014;29:103–17. Uses a genetic approach to show that prolongation of osteocyte lifespan exaggerates age-dependent development of cortical porosity in mice.PubMedCrossRef
55.
Schneider P, Krucker T, Meyer E, Ulmann-Schuler A, Weber B, Stampanoni M, et al. Simultaneous 3D visualization and quantification of murine bone and bone vasculature using micro-computed tomography and vascular replica. Microsc Res Tech. 2009;72(9):690–701.PubMedCrossRef
56.
Nelson JF, Felicio LS, Osterburg HH, Finch CE. Differential contributions of ovarian and extraovarian factors to age-related reductions in plasma estradiol and progesterone during the estrous cycle of C57BL/6J mice. Endocrinology. 1992;130:805–10.PubMed
57.
Mobbs CV, Cheyney D, Sinha YN, Finch CE. Age-correlated and ovary-dependent changes in relationships between plasma estradiol and luteinizing homrone, prolactin, and growth hormone in female C57BL/6J mice. Endocrinology. 1985;116:813–20.PubMedCrossRef
58.
Finch CE, Jonec V, Wisner Jr JR, Sinha YN, de Vellis JS, Swerdloff RS. Hormone production by the pituitary and testes of male C57BL/6J mice during aging. Endocrinology. 1977;101(4):1310–7.PubMedCrossRef
59.
Mullender MG, van der Meer DD, Huiskes R, Lips P. Osteocyte density changes in aging and osteoporosis. Bone. 1996;18(2):109–13.PubMedCrossRef
60.
Mori S, Harruff R, Ambrosius W, Burr DB. Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures. Bone. 1997;21(6):521–6.PubMedCrossRef
61.
Qiu S, Rao DS, Palnitkar S, Parfitt AM. Age and distance from the surface but not menopause reduce osteocyte density in human cancellous bone. Bone. 2002;31(2):313–8.PubMedCrossRef
62.
Busse B, Djonic D, Milovanovic P, Hahn M, Puschel K, Ritchie RO, et al. Decrease in the osteocyte lacunar density accompanied by hypermineralized lacunar occlusion reveals failure and delay of remodeling in aged human bone. Aging Cell. 2010;9(6):1065–75.PubMedCrossRef
63.
Torres-Lagares D, Tulasne JF, Pouget C, Llorens A, Saffar JL, Lesclous P. Structure and remodelling of the human parietal bone: an age and gender histomorphometric study. J Craniomaxillofac Surg. 2010;38(5):325–30.PubMedCrossRef
64.
Joiner DM, Tayim RJ, McElderry JD, Morris MD, Goldstein SA. Aged male rats regenerate cortical bone with reduced osteocyte density and reduced secretion of nitric oxide after mechanical stimulation. Calcif Tissue Int. 2014;94(5):484–94.PubMedCrossRef
65.
66.••
Carter Y, Thomas CD, Clement JG, Cooper DM. Femoral osteocyte lacunar density, volume and morphology in women across the lifespan. J Struct Biol. 2013;183(3):519–26. Shows decrease in osteocyte lacunar volume in elderly humans using 3-dimensional measurements.PubMedCrossRef
67.•
Kobayashi K, Nojiri H, Saita Y, Morikawa D, Ozawa Y, Watanabe K, et al. Mitochondrial superoxide in osteocytes perturbs canalicular networks in the setting of age-related osteoporosis. Sci Rep. 2015;16(5):9148. Shows that oxidative stress increases in osteocytes of aged mice.CrossRef
68.••
Milovanovic P, Zimmermann EA, Hahn M, Djonic D, Puschel K, Djuric M, et al. Osteocytic canalicular networks: morphological implications for altered mechanosensitivity. ACS Nano. 2013;7(9):7542–51. Shows reduced osteocyte connectivity in cortical bone of aged humans.PubMedCrossRef
69.•
Lopez-Otin C, Serrano M, Partridge L, Blasco MA, Kroemer G. The Hallmarks of aging. Cell. 2013;153(6). Authoritative review of current concepts of molecular causes of age-related changes in cell function and behavior.
70.
Tonna EA. Accumulation of lipofuscin (age pigment) in aging skeletal connective tissues as revealed by electron microscopy. J Gerontol. 1975;30(1):3–8.PubMedCrossRef
71.
Brunk UT, Terman A. Lipofuscin: mechanisms of age-related accumulation and influence on cell function. Free Radic Biol Med. 2002;33(5):611–9.PubMedCrossRef
72.
73.
Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, et al. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol. 2005;169(3):425–34.PubMedPubMedCentralCrossRef
74.
Komatsu M, Wang QJ, Holstein GR, Friedrich Jr VL, Iwata J, Kominami E, et al. Essential role for autophagy protein Atg7 in the maintenance of axonal homeostasis and the prevention of axonal degeneration. Proc Natl Acad Sci U S A. 2007;104(36):14489–94.PubMedPubMedCentralCrossRef
75.
Zhang CF, Gruber F, Ni C, Mildner M, Koenig U, Karner S, et al. Suppression of autophagy dysregulates the antioxidant response and causes premature senescence of melanocytes. J Invest Dermatol. 2015;135(5):1348–57.PubMedCrossRef
76.
Stranks AJ, Hansen AL, Panse I, Mortensen M, Ferguson DJ, Puleston DJ, et al. Autophagy controls acquisition of aging features in macrophages. J Innate Immun. 2015;7(4):375–91.PubMedCrossRef
77.
Pua HH, Guo J, Komatsu M, He YW. Autophagy is essential for mitochondrial clearance in mature T lymphocytes. J Immunol. 2009;182(7):4046–55.PubMedCrossRef
78.
Jung HS, Chung KW, Won KJ, Kim J, Komatsu M, Tanaka K, et al. Loss of autophagy diminishes pancreatic beta cell mass and function with resultant hyperglycemia. Cell Metab. 2008;8(4):318–24.PubMedCrossRef
79.
Carnio S, LoVerso F, Baraibar MA, Longa E, Khan MM, Maffei M, et al. Autophagy impairment in muscle induces neuromuscular junction degeneration and precocious aging. Cell Rep. 2014;8(5):1509–21.PubMedPubMedCentralCrossRef
80.
Mortensen M, Soilleux EJ, Djordjevic G, Tripp R, Lutteropp M, Sadighi-Akha E, et al. The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance. J Exp Med. 2011;208(3):455–67.PubMedPubMedCentralCrossRef
81.
Warr MR, Binnewies M, Flach J, Reynaud D, Garg T, Malhotra R, et al. FOXO3A directs a protective autophagy program in haematopoietic stem cells. Nature. 2013;494(7437):323–7.PubMedPubMedCentralCrossRef
82.•
Onal M, Piemontese M, Xiong J, Wang Y, Han L, Ye S, et al. Suppression of autophagy in osteocytes mimics skeletal aging. J Biol Chem. 2013;288(24):17432–40. Demonstrates importance of autophagy in osteocytes to murine skeletal homeostasis.PubMedPubMedCentralCrossRef
83.
Dupont N, Jiang S, Pilli M, Ornatowski W, Bhattacharya D, Deretic V. Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1beta. EMBO J. 2011;30(23):4701–11.PubMedPubMedCentralCrossRef
84.
Narita M, Young AR, Arakawa S, Samarajiwa SA, Nakashima T, Yoshida S, et al. Spatial coupling of mTOR and autophagy augments secretory phenotypes. Science. 2011;332(6032):966–70.PubMedPubMedCentralCrossRef
85.
Liu F, Fang F, Yuan H, Yang D, Chen Y, Williams L, et al. Suppression of autophagy by FIP200 deletion leads to osteopenia in mice through the inhibition of osteoblast terminal differentiation. J Bone Miner Res. 2013;28(11):2414–30.PubMedPubMedCentralCrossRef
86.
Gan B, Peng X, Nagy T, Alcaraz A, Gu H, Guan JL. Role of FIP200 in cardiac and liver development and its regulation of TNFalpha and TSC-mTOR signaling pathways. J Cell Biol. 2006;175(1):121–33.PubMedPubMedCentralCrossRef
87.
Nollet M, Santucci-Darmanin S, Breuil V, Al-Sahlanee R, Cros C, Topi M, et al. Autophagy in osteoblasts is involved in mineralization and bone homeostasis. Autophagy. 2014;10(11):1965–77.PubMedPubMedCentralCrossRef
88.•
Chen K, Yang YH, Jiang SD, Jiang LS. Decreased activity of osteocyte autophagy with aging may contribute to the bone loss in senile population. Histochem Cell Biol. 2014;142(3):285–95. Shows that expression of genes required for autophagy decline in rat osteocytes.PubMedCrossRef
89.
Luo D, Ren H, Li T, Lian K, Lin D. Rapamycin reduces severity of senile osteoporosis by activating osteocyte autophagy. Osteoporos Int. 2015;Sep 22.
90.
Wilkinson CW, Petrie EC, Murray SR, Colasurdo EA, Raskind MA, Peskind ER. Human glucocorticoid feedback inhibition is reduced in older individuals: evening study. J Clin Endocrinol Metab. 2001;86(2):545–50.PubMed
91.
Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin N Am. 2012;41(3):595–611.CrossRef
92.
Weinstein RS, Wan C, Liu Q, Wang Y, Almeida M, O'Brien CA, et al. Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged mice. Aging Cell. 2010;9:147–61.PubMedPubMedCentralCrossRef
93.
Xia X, Kar R, Gluhak-Heinrich J, Yao W, Lane NE, Bonewald LF, et al. Glucocorticoid-induced autophagy in osteocytes. J Bone Miner Res. 2010;25(11):2479–88.PubMedPubMedCentralCrossRef
94.
Piemontese M, Onal M, Xiong J, Wang Y, Almeida M, Thostenson JD, et al. Suppression of autophagy in osteocytes does not modify the adverse effects of glucocorticoids on cortical bone. Bone. 2015;75:18–26.PubMedCrossRef
95.
96.
Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012;19(1):107–20.PubMedPubMedCentralCrossRef
97.
Marino G, Niso-Santano M, Baehrecke EH, Kroemer G. Self-consumption: the interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol. 2014;15(2):81–94.PubMedPubMedCentralCrossRef
98.
Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15(1):49–63.PubMedCrossRef
99.
Noble BS, Stevens H, Loveridge N, Reeve J. Identification of apoptotic changes in osteocytes in normal and pathological human bone. Bone. 1997;20(3):273–82.PubMedCrossRef
100.
101.
102.
Li F, Huang Q, Chen J, Peng Y, Roop DR, Bedford JS, et al. Apoptotic cells activate the “phoenix rising” pathway to promote wound healing and tissue regeneration. Sci Signal. 2010;3(110):ra13.PubMedPubMedCentral
103.
Yang J, Shah R, Robling AG, Templeton E, Yang H, Tracey KJ, et al. HMGB1 is a bone-active cytokine. J Cell Physiol. 2008;214(3):730–9.PubMedCrossRef
104.
Bidwell JP, Yang J, Robling AG. Is HMGB1 an osteocyte alarmin? J Cell Biochem. 2008;103(6):1671–80.PubMedCrossRef
105.
Almeida M, Han L, Ambrogini E, Weinstein RS, Manolagas SC. Glucocorticoids and tumor necrosis factor {alpha} increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem. 2011;286(52):44326–35.PubMedPubMedCentralCrossRef
106.
Noble BS, Peet N, Stevens HY, Brabbs A, Mosley JR, Reilly GC, et al. Mechanical loading: biphasic osteocyte survival and targeting of osteoclasts for bone destruction in rat cortical bone. Am J Physiol Cell Physiol. 2003;284(4):C934–43.PubMedCrossRef
107.
Hamrick MW, Ding KH, Pennington C, Chao YJ, Wu YD, Howard B, et al. Age-related loss of muscle mass and bone strength in mice is associated with a decline in physical activity and serum leptin. Bone. 2006;39(4):845–53.PubMedCrossRef
Metadata
Title
The Role of Osteocytes in Age-Related Bone Loss
Authors
Robert L. Jilka
Charles A. O’Brien
Publication date
01-02-2016
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 1/2016
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-016-0297-0

Other articles of this Issue 1/2016

Current Osteoporosis Reports 1/2016 Go to the issue

Skeletal Biology and Regulation (MR Forwood and A Robling, Section Editors)

Osteoblastic Actions of the Neuropeptide Y System to Regulate Bone and Energy Homeostasis

Skeletal Development (E Schipani and E Zelzer, Section Editors)

SOXC Genes and the Control of Skeletogenesis

Rare Bone Disease (CB Langman and E Shore, Section Editors)

Advances in the Classification and Treatment of Osteogenesis Imperfecta

Epidemiology and Pathophysiology (J Cauley and B Dawson-Hughes, Section Editors)

Aberrant Myeloid Differentiation Contributes to the Development of Osteoporosis in Neurofibromatosis Type 1